HEPLISAV

BIOLOGICAL5 trials

Sponsors

Dynavax Technologies Corporation

Conditions

Chronic Kidney DiseaseEnd Stage Renal DiseaseHealthyHepatitis B

Phase 1

A Study of the Immune Response to Heplisav in Healthy Older Adults

CompletedNCT01999699

Dynavax Technologies CorporationHepatitis B

Start: 2013-11-30End: 2015-03-31Updated: 2019-03-20

Phase 2

Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine

CompletedNCT00511095

Dynavax Technologies CorporationHepatitis B

Start: 2007-06-30End: 2008-03-31Updated: 2019-04-30

Phase 3

Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis

CompletedNCT01195246

Dynavax Technologies CorporationEnd Stage Renal Disease

Start: 2010-12-31End: 2012-08-31Updated: 2019-03-20

Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine

CompletedNCT02117934

Dynavax Technologies CorporationHealthy

Start: 2014-04-30End: 2015-10-31Updated: 2019-03-20

Unknown Phase

Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease

CompletedNCT01282762

Dynavax Technologies CorporationChronic Kidney Disease

Start: 2010-12-31End: 2013-08-31Updated: 2019-03-20

Related Papers

Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease

Vaccine2023-04-1919 citations

Immunogenicity and safety of a 2-dose hepatitis B vaccine, HBsAg/CpG 1018, in persons with diabetes mellitus aged 60–70 years

Vaccine2019-08-1751 citations

Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults

Vaccine2017-12-27185 citations